Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 May 2025 | Story André Damons | Photo Supplied
Prof Martin Nyaga
Prof Martin Nyaga, Full Professor in the Division of Virology and Head of the Next Generation Sequencing Unit (UFS-NGS Unit) at the University of the Free State.

Prof Martin Nyaga, an NRF B-Rated Full Professor in the Division of Virology and Head of the Next Generation Sequencing (UFS-NGS) Unit at the University of the Free State (UFS), has been selected as one of the cohort II fellows of the prestigious Calestous Juma Science Leadership Fellowship

Prof Nyaga, who is one of 12 individuals from six African countries (Ethiopia, Ghana, Kenya, Malawi, South Africa, and Zambia) selected to this cohort, says he is profoundly honoured. Through the prestigious fellowship, inspired by Professor Juma’s visionary legacy, he envisions advancing Africa’s capacity to combat infectious diseases by developing robust, mNGS-based surveillance systems that detect and characterise emerging pathogens early enough.

“The opportunity to join a cohort of exceptional African scientists, united by a shared commitment to addressing global health challenges, is both humbling and inspiring. I feel a deep sense of responsibility to uphold the fellowship’s mission of fostering sustainable development through cutting-edge research and policy engagement, particularly in the context of my work on genomic disease surveillance. 

“I am deeply inspired by Professor Calestous Juma’s legacy of harnessing science for sustainable development, and I am committed to embodying his optimism and interdisciplinary approach. The fellowship represents a transformative platform to advance scientific innovation and leadership in Africa. I would like to extend my gratitude to the Gates Foundation for this opportunity, and I look forward to contributing to a transformative era of African scientific leadership,” says Prof Nyaga.

 

Advantages of the Fellowship

The Calestous Juma Science Leadership Fellowship focuses on bringing together accomplished innovators to form a community of global health opinion shapers and influencers. The programme provides targeted professional development to support fellows as they expand their networks, amplify their voices, and continue to build and strengthen a dynamic, resilient research & development (R&D) ecosystem that changes the lives of people living not only in Africa but around the world.

Among the new cohort are experts in virology (including HIV and rota), bacteriology (including TB and strep), immunology, malaria, modelling, maternal immunisation, epidemiology, chemistry, drug discovery and development, vaccine discovery, clinical trials, and controlled human infection models to name just a few examples. 

According to Prof Nyaga, Director of a WHO Collaborating Centre for Vaccine Preventable Diseases (VPD) Surveillance and Pathogen Genomics, selection for the Fellowship is a rigorous and competitive process, designed to identify African scientists with exceptional research portfolios and leadership potential. Candidates are typically invited based on their established track record in transformative science, as well as their ability to anchor health and R&D initiatives within their communities. Successful applicants are evaluated for their scientific excellence, interdisciplinary networks, and commitment to mentoring the next generation of African scientists, aligning with the fellowship’s holistic view of leadership.

The NRF B3-rated scientist says he is eager to engage with the fellowship’s vibrant community of scientists from multiple African countries, fostering collaborations that amplify our collective impact on global health. He anticipates benefiting from the fellowship’s non-scientific training in communication, policy engagement, and institution strengthening. Participating in networking opportunities will broaden his perspectives and strengthen his capacity to drive innovative solutions in Africa’s genomic R&D ecosystem.

“I believe my work in pathogen surveillance research using genomics, aligns closely with the fellowship's objectives. As a fellow, I bring a wealth of experience in leading multi-country projects, establishing regional collaborations, and fostering capacity development through training and mentorship. 

“In addition, my ongoing work at the UFS-NGS Unit, including projects on enteric and respiratory virus surveillance, vaccine monitoring and efficacy using next generation sequencing, which will enrich discussions on public health. Conversely, the fellowship will enhance my scientific development by providing advanced training in leadership and policy advocacy, enabling me to translate research findings into actionable health policies. This synergy will elevate my capacity to lead transformative R&D initiatives and mentor future African scientists.” 

 

Contributing to the betterment of people 

Prof Nyaga believes his research on vaccine efficacy and metagenomics of gut and respiratory virome will contribute to the betterment of not only Africans, but also people around the world by informing targeted interventions in vaccine efficacy monitoring and development. This research will also contribute to the reduction of morbidity and mortality applicable to enteric and respiratory infections in vulnerable populations. 

Furthermore, he explains, the fellowship’s emphasis on networking and policy engagement will amplify these efforts, enabling him to advocate for evidence-based health policies across Africa. Globally, their collective work as Calestous Juma Science Leadership fellows will strengthen the R&D ecosystem, fostering innovation that addresses pandemic preparedness and other health challenges. By building resilient scientific communities, the fellowship will contribute to sustainable development, improving lives in Africa and beyond.

News Archive

Fighting the tuberculosis battle as a collective
2015-09-28



The team hard at work making South Africa a
healthier place

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent. More than 95% of TB deaths occur in low- and middle-income countries. Despite being more prevalent among men than women, TB remains one of the top five causes of death amongst women between the ages of 15 and 44 years. While everyone is at risk for contracting TB, those most at risk include children under the age of five and the elderly. In addition, research indicates that individuals with compromised immune systems, household contacts with pulmonary TB patients, and healthcare workers are also at increased risk for contracting TB.

According to the Deputy Director of the Centre for Health Systems Research and Development (CHSR&D) at the UFS, Dr Michelle Engelbrecht, research has found that healthcare workers may be three times more likely to be infected by TB than the general population.

The unsettling fact

“Research done in health facilities in South Africa has found that nurses do not often participate in basic prevention acts, such as opening windows and wearing respirators when attending to infectious TB patients,” she explained. 

In response to this concern, CHSR&D, which operates within the Faculty of Humanities at the the University of the Free State (UFS) Bloemfontein Campus has developed a research project to investigate TB prevention and infection control in primary healthcare facilities and households in Mangaung Metropolitan.

Action to counter the statistics

A team of four researchers and eight field workers from CHSR&D are in the process of gathering baseline data from the 41 primary healthcare facilities in Mangaung. The baseline comprises a facility assessment conducted with the TB nurse, and observations at each of the facilities. Individual interviews are also conducted with community caregivers, as well as TB and general patients. Self-administered questionnaires on knowledge, attitudes, and practices about TB infection control are completed by all nurses and facility-based community caregivers.

Healthcare workers are the main focus of this research, given their increased risk of acquiring TB in healthcare settings. At clinics, interventions will be developed to improve infection control practices by both healthcare workers and patients. TB patients’ households are also visited to screen household contacts for TB. Those found to have symptoms suggesting TB infection are referred to the clinics for further assessment and treatment.

The findings of this study will serve to inform the development of an intervention to address TB prevention and infection control in primary healthcare facilities. Further funding will be sought to implement and evaluate the intervention.

Curbing future infections and subsequent deaths as a result of TB is the priority for the UFS. The cooperation and collaboration of the community, government, and sponsors will ensure that this project is a success, hence prolonging life expectancy.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept